Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleOMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis

PETER A. MERKEL, SIBEL Z. AYDIN, MAARTEN BOERS, HANER DIRESKENELI, KAREN HERLYN, PHILIP SEO, RAVI SUPPIAH, GUNNAR TOMASSON and RAASHID A. LUQMANI
The Journal of Rheumatology July 2011, 38 (7) 1480-1486; DOI: https://doi.org/10.3899/jrheum.110276
PETER A. MERKEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pmerkel@bu.edu
SIBEL Z. AYDIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAARTEN BOERS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANER DIRESKENELI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAREN HERLYN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PHILIP SEO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAVI SUPPIAH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GUNNAR TOMASSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAASHID A. LUQMANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

There has been a marked increase in the past 15 years in the number and quality of clinical trials in the idiopathic inflammatory vasculitides, especially the small-vessel vasculitides known as antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis [AAV; granulomatosis, with polyangiitis (Wegener’s)]. These trials have been conducted by multicenter, international groups in Europe and the United States with financial support provided by government agencies and biopharmaceutical companies. This increased clinical trial activity in vasculitis has been accompanied by the development and validation of new outcome measures — a challenging process for these complex, multiorgan system diseases. The international OMERACT Vasculitis Working Group has developed and implemented an iterative research agenda that has utilized accumulated experience and datasets from several multicenter clinical trials and large cohort studies. This work has led to the development, evaluation, validation, and endorsement, through the OMERACT consensus and validation processes, of a “core set” of outcome measurements for use in clinical trials of AAV. The core set includes domains of disease activity, damage assessment, patient-reported outcomes, and mortality; there is at least one validated outcome measurement instrument available for each domain. This report reviews the domains of illness in AAV included in the OMERACT core set, describes the instruments validated to measure these domains, and presents the approved core set.

Key Indexing Terms:
  • VASCULITIS
  • OUTCOMES
  • ACTIVITY
  • DAMAGE
  • QUALITY OF LIFE

Footnotes

  • The OMERACT Vasculitis Working Group is supported by the Vasculitis Clinical Research Consortium through The National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319, U01 AR51874, and P60 AR047785) and the National Center for Research Resources/NIH: U54 RR01949703. The Vasculitis Clinical Research Consortium is part of the NIH Rare Diseases Clinical Research Network (www.RareDiseasesNetwork.org/vcrc).

View Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 7
1 Jul 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
PETER A. MERKEL, SIBEL Z. AYDIN, MAARTEN BOERS, HANER DIRESKENELI, KAREN HERLYN, PHILIP SEO, RAVI SUPPIAH, GUNNAR TOMASSON, RAASHID A. LUQMANI
The Journal of Rheumatology Jul 2011, 38 (7) 1480-1486; DOI: 10.3899/jrheum.110276

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
PETER A. MERKEL, SIBEL Z. AYDIN, MAARTEN BOERS, HANER DIRESKENELI, KAREN HERLYN, PHILIP SEO, RAVI SUPPIAH, GUNNAR TOMASSON, RAASHID A. LUQMANI
The Journal of Rheumatology Jul 2011, 38 (7) 1480-1486; DOI: 10.3899/jrheum.110276
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CORE SET DOMAIN: DISEASE ACTIVITY ASSESSMENT
    • CORE SET DOMAIN: DISEASE DAMAGE ASSESSMENT
    • CORE SET DOMAIN: MORTALITY
    • CORE SET DOMAIN: PATIENT-REPORTED OUTCOMES: HEALTH-RELATED QUALITY OF LIFE
    • OMERACT CORE SET OF OUTCOME MEASURES FOR AAV
    • RESEARCH AGENDA FOR THE OMERACT VASCULITIS WORKING GROUP
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

OMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

  • Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials
  • Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System
  • A Systematic Literature Review Analysis of Ultrasound Joint Count and Scoring Systems to Assess Synovitis in Rheumatoid Arthritis According to the OMERACT Filter
Show more OMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

Disease-specific Outcomes

  • Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review
  • Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10
  • Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
Show more Disease-specific Outcomes

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire